Clinical Trial Update: A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating all-trans retinoic acid and bryostatin in patients with acute myeloid leukemia and myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• Bryostatin (Bryostatin-1)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED